Recontacting non-BRCA1/2 breast cancer patients for germline CHEK2 c.1100del pathogenic variant testing: uptake and patient experiences

BACKGROUND: CHEK2 has been recognized as a breast cancer risk gene with moderate effect. Women who have previously tested negative for a BRCA1/2 gene germline pathogenic variant may benefit from additional genetic testing for the CHEK2 c.1100del pathogenic variant. The aims of this study were: 1) to...

Descripción completa

Detalles Bibliográficos
Autores principales: Velthuizen, Mary E., van der Luijt, Rob B., de Vries, Beja J., Koudijs, Marco J., Bleiker, Eveline M. A., Ausems, Margreet G. E. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7814590/
https://www.ncbi.nlm.nih.gov/pubmed/33468213
http://dx.doi.org/10.1186/s13053-021-00166-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7814590/
https://www.ncbi.nlm.nih.gov/pubmed/33468213
http://dx.doi.org/10.1186/s13053-021-00166-1

Ejemplares similares